InVivo Therapeutics CEO Frank Reynolds Named to Irish Small Business 50 by the Irish Echo

InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that the Irish Echo, the Country’s largest circulation Irish American weekly newspaper, has named Frank Reynolds, CEO of InVivo Therapeutics, to its inaugural Irish Small Business 50 list. The Irish Small Business 50 recognizes entrepreneurs and business leaders that represent the values of the Irish American community and their entrepreneurial achievements. Inductees will be featured in an upcoming issue of the Irish Echo and honored at a gala dinner on Friday, April 15^th in New York City.

"As a first generation Irish American, it gives me pride to see the entrepreneurial spirit of our community recognized,” said Frank Reynolds, CEO of InVivo Therapeutics. "It is an honor to be named to the inaugural Irish Small Business 50 and to be acknowledged by ‘the Echo’ for what we have accomplished at InVivo Therapeutics. Our team works tirelessly each day toward bringing the promise of our groundbreaking new technologies to those who have suffered spinal cord injuries.”

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston. For more information on InVivo Therapeutics, please visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.